Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Janette Priefert
Manager, Clinical Data
College of Medicine - Phoenix
Full Page
Overview
Research
More
Collaboration
(12)
Mrinalini Kala
Mutual work: 4 Grants﹒4 Proposals
Collaboration Details
Mason Burchfield
Mutual work: 4 Grants﹒6 Proposals
Collaboration Details
Elena Young
Mutual work: 6 Proposals﹒4 Grants
Collaboration Details
Raeven Maxwell
Mutual work: 1 Proposal
Collaboration Details
Roderick Tung
Mutual work: 1 Proposal
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(8)
RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Active
·
2023
·
$0 / $1.8M
·
External
viral persistence,
immune dysregulation,
intervention evaluation,
post-acute sequelae,
viral reactivation
RECOVER-NEURO: A Platform Protocol for Evaluation of Interventions for Cognitive Dysfunction in Post-Acute Sequelae of SARSCoV- 2 Infection (PASC)
Active
·
2023
·
$0 / $729.8K
·
External
neurology,
cognitive dysfunction,
intervention evaluation,
post-acute sequelae,
sars-cov-2 infection
RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Active
·
2023
·
$0 / $5.5K
·
External
sleep disturbances,
interventions,
sars-cov-2,
evaluation,
post-acute sequelae
RECOVER-NEURO: A Platform Protocol for Evaluation of Interventions for Cognitive Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Active
·
2023
·
$0 / $5K
·
External
neuroscience,
cognitive dysfunction,
sars-cov-2,
intervention,
evaluation
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR00l (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congeni
Active
·
2022
·
$0 / $277.2K
·
External
glucocorticoid reduction,
adult subjects
Page 1 of 2
Previous page
Next page
